Abstract
Liver metastases from colorectal cancer (CRC) have a poor prognosis. Despite recent advances in the management of advanced disease with chemotherapy, liver resection remains the only hope for cure for patients with colorectal liver metastases. Approximately 15% of patients with stage IV CRC referred to specialist centers have metastatic liver disease deemed to be resectable at presentation. Over the last five years, combination chemotherapeutic regimens, namely 5-fluorouracil/folinic acid with irinotecan or oxaliplatin and, more recently, integrating targeted monoclonal antibodies, have been shown to downsize the tumour burden to an extent that sometimes allows initially unresectable metastases to be excised. Five-year survival rates following liver resection range between 25% and 55% compared with 0% and 5% for non-operated patients. Beyond liver resection, the rationale for “pseudo-adjuvant” chemotherapy lacks scientific evidence, despite some promising data. However, perioperative chemotherapy for resectable lesions is gaining ground in current practice. In this article we review the state of the art treatment for CRC liver metastases and, considering the results of recent trials, try to determine the appropriate role of chemotherapy.
Keywords: Colorectal liver metastases treatment, review
Reviews on Recent Clinical Trials
Title: Treatment of Colorectal Liver Metastases: A Review
Volume: 4 Issue: 1
Author(s): M. Van den Eynde and A. Hendlisz
Affiliation:
Keywords: Colorectal liver metastases treatment, review
Abstract: Liver metastases from colorectal cancer (CRC) have a poor prognosis. Despite recent advances in the management of advanced disease with chemotherapy, liver resection remains the only hope for cure for patients with colorectal liver metastases. Approximately 15% of patients with stage IV CRC referred to specialist centers have metastatic liver disease deemed to be resectable at presentation. Over the last five years, combination chemotherapeutic regimens, namely 5-fluorouracil/folinic acid with irinotecan or oxaliplatin and, more recently, integrating targeted monoclonal antibodies, have been shown to downsize the tumour burden to an extent that sometimes allows initially unresectable metastases to be excised. Five-year survival rates following liver resection range between 25% and 55% compared with 0% and 5% for non-operated patients. Beyond liver resection, the rationale for “pseudo-adjuvant” chemotherapy lacks scientific evidence, despite some promising data. However, perioperative chemotherapy for resectable lesions is gaining ground in current practice. In this article we review the state of the art treatment for CRC liver metastases and, considering the results of recent trials, try to determine the appropriate role of chemotherapy.
Export Options
About this article
Cite this article as:
Eynde Van den M. and Hendlisz A., Treatment of Colorectal Liver Metastases: A Review, Reviews on Recent Clinical Trials 2009; 4 (1) . https://dx.doi.org/10.2174/157488709787047558
DOI https://dx.doi.org/10.2174/157488709787047558 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenetics in Geriatric Medicine: Challenges and Opportunities for Clinical Practice
Current Drug Metabolism A Validated Stability-Indicating HPTLC Method for the Estimation of Capecitabine in its Tablet Dosage Form
Current Pharmaceutical Analysis Recent Developments in the Field of Anticancer Platinum Complexes
Recent Patents on Anti-Cancer Drug Discovery Application of a Deep Matrix Factorization Model on Integrated Gene Expression Data
Current Bioinformatics Targeted Therapies in Head and Neck Cancer: Past, Present and Future
Reviews on Recent Clinical Trials Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Targeting the Tumor Stroma in Cancer Therapy
Current Pharmaceutical Biotechnology The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Current Pharmaceutical Design The Role of 3D Pharmacophore Mapping Based Virtual Screening for Identification of Novel Anticancer Agents: An Overview
Current Topics in Medicinal Chemistry Antibodies and their Multivalent Constructs for Cancer Therapy
Protein & Peptide Letters Pharmacokinetics and Systems Pharmacology of Anti-CD47 Macrophage Immune Checkpoint Inhibitor Hu5F9-G4
Current Pharmacogenomics and Personalized Medicine Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease
Current Pharmaceutical Design Characterization of Cepharanthin Nanosuspensions and Evaluation of Their In Vitro Activity for the HepG2 Hepatocellular Carcinoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry Quality of Life Assessments in Colorectal Cancer Surgery. A Review
Current Cancer Therapy Reviews Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery MicroRNAs as Critical Regulators Involved in Regulating Epithelial- Mesenchymal Transition
Current Cancer Drug Targets Polyphenolic Coumpounds in Chemoprevention of Colon Cancer - Targets and Signaling Pathways
Anti-Cancer Agents in Medicinal Chemistry Identification of Potential MEK1 Inhibitors by Pharmacophore-based Virtual Screening and MD Simulations
Letters in Drug Design & Discovery Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets